Hetero Biopharma
Hetero Biopharma is a Hyderabad-based biopharmaceutical company founded in 2009 that develops and manufactures biosimilars and other biologic medicines for global patients. It operates as a private mid-to-large scale manufacturer within India's biopharma sector.
- Company typePrivate
- Founded2009
- HeadquartersHyderabad, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hetero Biopharma does
Hetero Biopharma is a Hyderabad-headquartered biopharmaceutical company founded in 2009 that develops and manufactures biosimilars and other biologic medicines for global patients. The company operates as a private, for-profit entity within India's broader pharmaceutical manufacturing ecosystem, with a workforce in the 1,001–5,000 employee range indicating mid-to-large scale operations. Its corporate website and other public source channels captured here contain only placeholder content, so operational detail beyond firmographics is not available in the input.
The company's product focus on biosimilars — biologic medicines designed to be highly similar to approved reference biologics — places it within a regulated, capital-intensive segment of the pharmaceutical industry that requires specialized manufacturing infrastructure, analytical characterization capabilities, and regulatory approval pathways in multiple jurisdictions. The stated emphasis on serving "global patients" suggests a multi-market commercial orientation rather than purely domestic India distribution, though no specific geographies, products, or partners are confirmed in the source data. No technology stack, patents, or proprietary platform components are disclosed.
The underlying business model is consistent with biosimilar development, manufacturing, and commercial supply: revenue would be generated through the sale of approved biosimilar products to healthcare providers, distributors, and government procurement programs across multiple jurisdictions. The absence of disclosed pricing, customer, channel, or revenue detail in available source material limits further specificity on go-to-market mechanics, contract structures, or segment mix.
Hetero Biopharma firmographics
Firmographics- Name
- Hetero Biopharma
- Website
- https://heterobiopharma.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 1,001–5,000 employees
- Short description
- Hetero Biopharma is a Hyderabad-based biopharmaceutical company founded in 2009 that develops and manufactures biosimilars and other biologic medicines for global patients. It operates as a private mid-to-large scale manufacturer within India's biopharma sector.
- Ownership category
- akta.pro rank
Hetero Biopharma industry classification
Industry- Product category
- Biosimilars and Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration) (HLAAAHAK)
- akta.pro secondary industry
- Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
Keywords
Where Hetero Biopharma is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Markets served
Hetero Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales
Hetero Biopharma product offering
Product offeringCore offering
Hetero Biopharma develops and manufactures biosimilars and other biologic medicines for global patients. The company produces biologic drug substances and finished biologic drug products at scale from its Hyderabad, India manufacturing operations, supplying affordable biosimilar therapeutics to international markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Biosimilars and biologic medicines Developed and manufactured biosimilars and other biologic medicines intended for global patient populations, produced at large scale from the company's Hyderabad biomanufacturing operations.
Companies that use Hetero Biopharma
Customer profileIdeal customer profiles1 record
Hetero Biopharma technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Hetero Biopharma partnerships and signals
Strategic signalExpansion highlights2 records
Hetero Biopharma competitors and assessment
Company assessmentOthers
- Lonza Biologics: Global CDMO with leading mammalian cell culture and biosimilar contract manufacturing capabilities; an adjacent competitor for third-party manufacturing services and a benchmark for biologics manufacturing scale.
Broad incumbents
- Pfizer: Major biopharma with biosimilar partnerships (e.g., Hospira heritage, Remsima co-marketing) and broad specialty/biologic portfolio; competes both as originator and as biosimilar distributor in certain geographies.
- Amgen: Global biopharma originator that both defends its biologics franchise and has launched biosimilars (e.g., Amjevita, Kanjinti); competes with Hetero Biopharma in regulated markets while setting the reference-product benchmark.
Direct peers
- Aurobindo Pharma: India-based vertically integrated pharma company that expanded into biosimilars via its Aurobindo Biologics subsidiary; comparable scale, Hyderabad presence, and EM/regulated market mix.
- Zydus Cadila (Zydus Lifesciences): India-based pharma with a growing biosimilars portfolio including monoclonal antibodies and insulin; comparable vertically integrated developer/manufacturer serving global markets.
- Celltrion: Korean biosimilars pure-play that pioneered mAb biosimilars (Remsima/Inflectra) and operates large-scale mammalian cell culture manufacturing; a direct competitor in regulated and EM biosimilar markets.
- Dr. Reddy's Laboratories: India-based vertically integrated pharma company with a biosimilars pipeline and biologic manufacturing in Hyderabad; comparable in scale, regulatory posture, and EM market reach.
- Samsung Bioepis: Joint venture between Samsung Biologics and Biogen focused exclusively on biosimilars development and commercialization; directly comparable business model and target molecule categories.
- Biocon Biologics: India-based global biosimilars pure-play with commercialized products in mAb, insulin, and rhEPO categories; the closest direct peer given identical Hyderabad roots, vertical integration, and global market focus.
Emerging players
- Alvotech: Iceland-based biosimilars developer with large-scale manufacturing focused on mAb biosimilars including Humira and Stelara references; comparable as a focused biosimilar pure-play competing in similar regulated markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Hetero Biopharma social profiles
Digital presenceHetero Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hetero Biopharma leadership team
Management profileNumber of profiles
Hetero Biopharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hetero Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hetero Biopharma
What does Hetero Biopharma do?
Hetero Biopharma develops and manufactures biosimilars and other biologic medicines for global patients. The company produces biologic drug substances and finished biologic drug products at scale from its Hyderabad, India manufacturing operations, supplying affordable biosimilar therapeutics to international markets.
When was Hetero Biopharma founded?
Hetero Biopharma was founded in 2009. It employs 1,001 to 5,000 people.
Where is Hetero Biopharma based?
Hetero Biopharma is headquartered in Hyderabad, India, in the Asia region.
Who are Hetero Biopharma's main competitors?
Lonza Biologics is listed as an others. Broad incumbents are Pfizer and Amgen. Direct peers are Aurobindo Pharma, Zydus Cadila (Zydus Lifesciences), Celltrion, Dr. Reddy's Laboratories, Samsung Bioepis and Biocon Biologics. Alvotech is listed as an emerging player.
Does Hetero Biopharma have an API?
No public API is recorded for Hetero Biopharma.
What industry is Hetero Biopharma in?
Hetero Biopharma's product category is Biosimilars and Biopharmaceuticals. Its primary akta.pro industry code is HLAAAHAK, Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration), with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2836.